<ѻýҕl>Sublobar Resection the 'New Standard of Care' in Small-Sized NSCLC?ѻýҕl> Large randomized study shows non-inferiority to lobectomy Aug 08, 2022
<ѻýҕl>Hearing Loss Plagues Cancer Survivors No Matter the Type of Chemoѻýҕl> Ototoxicity reported in more than half of study patients who got platinum, taxanes, or both Aug 03, 2022
<ѻýҕl>Lorlatinib Reduces CNS Progression in ALK-Positive NSCLCѻýҕl> Post-hoc analysis of CROWN trial does find more central nervous system toxicity, however Jun 14, 2022
<ѻýҕl>A Better Way to Irradiate Lethal CNS Metastases?ѻýҕl> Randomized trial makes case for proton craniospinal irradiation for leptomeningeal spread Jun 08, 2022
<ѻýҕl>Tiragolumab Fails in Extensive-Stage Small Cell Lung Cancerѻýҕl> No change in survival when combined with atezolizumab and chemotherapy Jun 06, 2022
<ѻýҕl>Immunotherapy Rechallenge in NSCLC Yields Overall Survival Boostѻýҕl> Phase II trial sees "synergistic benefit" with checkpoint blockade and anti-angiogenesis Jun 04, 2022
<ѻýҕl>KRAS Inhibitor Shrinks Tumors in Over 40% of NSCLC Patientsѻýҕl> Median survival surpasses 1 year in heavily pretreated population Jun 03, 2022
<ѻýҕl>Durvalumab Combinations Push the Response Envelope in Unresectable NSCLCѻýҕl> Big increases in response, disease control with the addition of anti-CD73, anti-NKG2A agents May 02, 2022
<ѻýҕl>Stop Calling It Cancer; AI Gets a Win in Bladder Cancer; Lack of Price Transparencyѻýҕl> News, features, and commentary about cancer-related issues Apr 22, 2022
<ѻýҕl>Boosting Responses to Neoadjuvant Therapy in Resectable NSCLCѻýҕl> Multi-drug platform study identifies promising durvalumab-based combinations Apr 12, 2022
<ѻýҕl>Neoadjuvant Nivolumab a 'New Standard' in Lung Cancerѻýҕl> "Another quantum leap in lung cancer therapy," expert says Apr 12, 2022
<ѻýҕl>Longer-Term Sotorasib Data 'Encouraging' in KRAS-Mutated NSCLCѻýҕl> Prolonged tumor response seen in 2-year analysis Apr 11, 2022
<ѻýҕl>More Research Needed on Use of Premium Cigars, Report Findsѻýҕl> These cigars seem less dangerous than cigarettes -- but it's only because of how they are smoked Mar 10, 2022
<ѻýҕl>Cancer May Heighten Odds of Guillain-Barre Syndromeѻýҕl> Link strongest with hematologic malignancies as well as prostate, breast, and respiratory cancers Mar 03, 2022
<ѻýҕl>ARB-Cancer Link May Come Down to Cumulative Exposureѻýҕl> Does a new paper resolve the conflicting safety data on the popular antihypertensives? Mar 02, 2022
<ѻýҕl>Early Clinical Activity With CDK4/6 Inhibitor in Pretreated Mesotheliomaѻýҕl> Disease control in 54% of patients in first clinical evaluation of abemaciclib Feb 17, 2022
<ѻýҕl>Long-Term Survival Benefit in NSCLC With Another Anti-PD-1/L1 Drugѻýҕl> Significant improvements in OS, PFS with durvalumab after CRT for unresectable disease Feb 15, 2022
<ѻýҕl>Women More Likely to Experience Severe Toxicity of Cancer Treatmentsѻýҕl> Increased risk was particularly pronounced among those receiving immunotherapy Feb 14, 2022
<ѻýҕl>Dual HER2 Therapy Active in Previously Treated Lung Cancerѻýҕl> Disease control in 87% of HER2-mutant NSCLC treated with trastuzumab, pertuzumab, docetaxel Jan 27, 2022
<ѻýҕl>Bevacizumab Add-On No Help in Progressive EGFR-Mutant Lung Cancerѻýҕl> Single-agent osimertinib prevails in progressive, T790M-positive NSCLC Dec 02, 2021
<ѻýҕl>Tumor Volume-Adapted RT Leads to Good Lung Cancer Control With Low Toxicityѻýҕl> No recurrence at 1 year in 90% of cases with primary tumors, metastases, synchronous disease Nov 02, 2021
<ѻýҕl>Targeted RT Boosts PFS in Oligoprogressive Lung Cancerѻýҕl> Fivefold improvement in NSCLC but no benefit in oligoprogressive breast cancer Oct 25, 2021
<ѻýҕl>'You're Still Doing WHAT After Lung Cancer Surgery?!'ѻýҕl> But don't give up on hardened smokers, researcher urges Oct 19, 2021
<ѻýҕl>Newly Approved EGFR Drug Yields Meaningful Benefit in Rare NSCLCsѻýҕl> Oral tyrosine kinase inhibitor may serve patient population with high unmet need Oct 14, 2021
<ѻýҕl>Immunotherapy Combo Fails to Boost Survival in Limited-Disease SCLCѻýҕl> No PFS or OS improvement with consolidation nivolumab-ipilimumab after standard treatment Sep 29, 2021
<ѻýҕl>Radiation or Surgery in Early Lung Cancer: Does It Make a Difference?ѻýҕl> Ablative radiation still noninferior to VATS after longer follow-up Sep 24, 2021
<ѻýҕl>How Many Deaths Will New Cigarette Warnings Prevent?ѻýҕl> Modeling study comes up with big numbers Sep 24, 2021
<ѻýҕl>Top Science From the World Conference on Lung Cancerѻýҕl> In this podcast, we examine some of the most important studies presented at this year's meeting Sep 23, 2021 podcast
<ѻýҕl>Another Possible Option for HER2-Mutated Non-Small Cell Lung Cancerѻýҕl> More than half of patients responded to antibody-drug conjugate targeting HER2 Sep 19, 2021
<ѻýҕl>More Help on the Way for Lung Cancers With Exon 20 Mutations?ѻýҕl> Early trials of DZD9008 demonstrated responses in over a third of patients Sep 15, 2021
<ѻýҕl>Cancer Vaccine May Boost Anti-EGFR Efficacy in Non-Small Cell Lung Cancerѻýҕl> More than 90% disease control rate, hint of improved PFS in pilot trial Sep 14, 2021
<ѻýҕl>Novel ADC Promising in Certain Non-Squamous Lung Cancersѻýҕl> Response rate topped 50% in patients with EGFR wild-type tumors and high MET expression Sep 14, 2021
<ѻýҕl>More Data in Support of Surgery for Malignant Pleural Mesotheliomaѻýҕl> Six-month improvement in overall survival with surgery plus chemotherapy versus chemo alone Sep 13, 2021
<ѻýҕl>Meta-Analysis Confirms Benefits of Low-Dose CT Screening for Lung Cancerѻýҕl> LDCT associated with a 16% relative reduction in mortality versus no screening Sep 13, 2021
<ѻýҕl>Immuno-Oncology Combo Active in Recurrent EGFR/ALK Positive NSCLCѻýҕl> Responses in 42% of EGFR group, limited activity in ALK-rearranged lung cancer Sep 12, 2021
<ѻýҕl>Triplet Therapy Proves Safe in Resectable Malignant Pleural Mesotheliomaѻýҕl> Atezolizumab add-on offers promising outcomes in phase I trial Sep 12, 2021
<ѻýҕl>Durable Response with Immunotherapy Combos in NSCLC with Brain Metastasesѻýҕl> Analysis of CheckMate 9LA data and phase II study from Spain offer hope in advanced disease Sep 12, 2021
<ѻýҕl>Dual Immunotherapy Boosts Survival in Metastatic NSCLCѻýҕl> Benefit with durvalumab-tremelimumab may vary by PD-L1 expression, histology Sep 10, 2021
<ѻýҕl>Study Sheds Light on Physician-Assisted Suicide in Lung Cancer Patientsѻýҕl> Patients often did not consult with radiation or medical oncologists Sep 09, 2021
<ѻýҕl>Second-Line Combo Fails to Improve Survival in SCLCѻýҕl> No OS difference, but lurbinectedin-doxorubicin was less toxic than standard chemotherapy options Sep 09, 2021